Cargando…

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-line systemic therapy for advanced/metastatic CCA before en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bibeau, Kristen, Féliz, Luis, Lihou, Christine F., Ren, Haobo, Abou-Alfa, Ghassan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200396/ https://www.ncbi.nlm.nih.gov/pubmed/35544727 http://dx.doi.org/10.1200/PO.21.00414

Ejemplares similares

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

I BET on anti‐FGFR to fight cancer resistance
por: Benedetti, Rosaria, et al.
Publicado: (2019)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
por: Wang, Jing, et al.
Publicado: (2020)

FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
por: Saborowski, Anna, et al.
Publicado: (2020)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Osteocyte-Specific Deletion of Fgfr1 Suppresses FGF23
por: Xiao, Zhousheng, et al.
Publicado: (2014)

A Network Map of FGF-1/FGFR Signaling System
por: Raju, Rajesh, et al.
Publicado: (2014)

The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
por: Astolfi, Annalisa, et al.
Publicado: (2020)

FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
por: Rajendran, Ranjithkumar, et al.
Publicado: (2021)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation
por: Wiedlocha, Antoni, et al.
Publicado: (2021)

Targeting the FGF/FGFR axis and its co-alteration allies
por: Uehara, Y., et al.
Publicado: (2022)

Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa
por: Abou-Alfa, Ghassan
Publicado: (2020)

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
por: Blackwell, Christina, et al.
Publicado: (2016)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
por: Li, Yuan, et al.
Publicado: (2020)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Dual roles of endothelial FGF-2–FGFR1–PDGF-BB and perivascular FGF-2–FGFR2–PDGFRβ signaling pathways in tumor vascular remodeling
por: Hosaka, Kayoko, et al.
Publicado: (2018)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

FGF /FGFR Signal Induces Trachea Extension in the Drosophila Visual System
por: Chu, Wei-Chen, et al.
Publicado: (2013)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
por: Zuo, Wei, et al.
Publicado: (2020)

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
por: Santolla, Maria Francesca, et al.
Publicado: (2020)

FGF/FGFR signaling pathway involved resistance in various cancer types
por: Zhou, Yangyang, et al.
Publicado: (2020)

Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives
por: Loda, Alessandra, et al.
Publicado: (2022)

The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach
por: Rezzola, Sara, et al.
Publicado: (2019)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches
por: Pagano, Katiuscia, et al.
Publicado: (2022)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
por: Furugaki, Koh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2tnvfmbr7utg8aoiline18inle